A scalable multiplex miRNA profiling workflow for precision oncology research

The promise of precision oncology rests on our ability to reliably monitor tumor biology in real time. Circulating microRNAs (miRNAs) offer that opportunity, serving as potentially stable, non-invasive biomarkers linked to disease progression and therapeutic response; however, their adoption in routine practice remains constrained by technical hurdles. (1,2) Because cancer biology is governed by complex regulatory networks, reliable monitoring typically requires multi-marker signatures rather than single markers to achieve accuracy. (3,4)

While widely used and reliable, traditional singleplex quantitative PCR workflows may become challenging to scale as demand expands. Analyzing one target per reaction increases sample consumption, introduces technical variability from multiple pipetting steps, and prolongs turnaround times (TAT) for comprehensive profiling. These inefficiencies are particularly problematic when working with limited clinical research samples, such as FFPE sections, where splitting samples across multiple assays can lead to inaccurate results and wasted material.(5,6)

While next-generation sequencing (NGS) panels provide broad genomic insight, qPCR and digital PCR remain highly efficient and cost-effective solutions when the question is targeted, time-sensitive, or requires precise quantification. For known variants, confirmation testing and copy number analysis, qPCR and dPCR offer faster turnaround, simpler workflows, and lower per-sample complexity. By incorporating multiplexing strategies, clinical research laboratories can further expand throughput and assay coverage, maintaining efficiency while increasing the value of each run. This enables a scalable approach that complements NGS without replacing proven targeted workflows. This article presents an end-to-end, automation-compatible workflow that streamlines miRNA analysis and reduces variability, thereby enabling scalable, multi-center implementation.(5)

An automation-compatible digital PCR workflow for multiplex miRNA profiling

The practical value of this standardized approach was demonstrated in the miRquad study by Allegretti et al., which introduced a novel multiplex digital PCR assay for miRNA profiling in head and neck cancer. The authors designed and analytically validated a first-in-class multiplex assay relying on TaqMan Advanced chemistry to simultaneously detect a four-miRNA prognostic signature—miR-21-5p, miR-96-5p, miR-21-3p, and miR-429—within a single reaction. To enable multiplexing, the researchers switched from standard Applied Biosystems FAM-conjugated probes to a combination of fluorescent molecules, such as Applied Biosystems VIC, ABY, and Cy5, for the individual targets within a single reaction. The study demonstrated analytical concordance between multiplex and singleplex Applied Biosystems TaqMan qPCR assays while maintaining performance across tissue and liquid biopsy specimens.(5)

• Automated miRNA extraction: The workflow begins with automated RNA extraction to ensure the purity, consistency, and yield required for analytically sensitive downstream applications. In the miRquad study, Allegretti et al. used the Applied Biosystems MagMAX mirVana Total RNA Isolation Kit on the Thermo Scientific KingFisher Apex Purification System to isolate total RNA, including small RNAs. This magnetic bead-based technology enables reproducible miRNA recovery from diverse clinical research samples, such as FFPE sections, serum, saliva, and tissue. Compared to traditional organic or spin-column methods, the automated workflow involves fewer manual steps, reducing hands-on variability and contamination risk. The ability to process up to 96 samples per run further supports scalability for longitudinal studies and multi-center verification efforts.

View user guide for automated total RNA isolation:

• cDNA synthesis: Following automated extraction and quantification, purified miRNAs are converted into cDNA using the Applied Biosystems TaqMan Advanced miRNA cDNA Synthesis Kit. This workflow employs a universal reverse-transcription chemistry that generates a single cDNA pool encompassing all miRNA targets while preserving their original relative abundance. By avoiding target-specific RT primers, the approach reduces reaction bias and reduces the need for multiple reverse transcription steps when analyzing multi-marker panels. The resulting cDNA provides a consistent and scalable template for downstream qPCR or dPCR quantification.

Learn more about universal RT and TaqMan Advanced miRNA Assays:

• High-precision dPCR analysis: For applications requiring maximal analytical sensitivity and quantitative precision, the workflow incorporates the Applied Biosystems QuantStudio Absolute Q Digital PCR System. Using proprietary microfluidic array plate technology, each reaction is partitioned into 20,480 fixed microchambers, enabling analysis of more than 95 percent of the input volume and minimizing sample waste. This high degree of partitioning supports absolute quantification without standard curves and increases tolerance to PCR inhibitors. The platform also supports multiplexing of up to four targets per reaction, allowing robust detection of low-abundance miRNAs that may fall below the sensitivity threshold of conventional qPCR.

Explore Absolute Q Digital PCR System:

• Advanced data analysis: For digital PCR, the Applied Biosystems Absolute Q software enables absolute quantification without standard curves, automatically calculating precision, confidence intervals, and dilution factors. Automated multi-channel thresholding improves partition classification in complex matrices, while Study Mode supports batch analysis across large cohorts.

Watch the virtual software demo

In the miRquad study by Allegretti et al., this standardized workflow facilitated the longitudinal evaluation of head and neck cancer samples, revealing that individuals with unfavorable outcomes exhibited measurable increases in the miRNA signature as early as 15 days post-surgery.(5)

By reducing sample amounts, minimizing technical variability (e.g., pipetting errors), and demonstrating high reproducibility across multiple centers, the study establishes a robust and scalable framework for real-time, non-invasive disease research.(5)

Implications in translational oncology research

Beyond this example, the impact of standardized extraction-to-digital-PCR workflows is evident across multiple translational oncology settings.

In metastatic melanoma research samples, for example, the  QuantStudio Absolute Q system enabled analytically-sensitive detection of low-abundance circulating miRNAs used to generate the miRatio, defined as the ratio between oncogenic miR-4488 and tumor-suppressive miR-579-3p. While miR-4488 was often undetectable by conventional qPCR in healthy donor serum, digital PCR reliably quantified its baseline expression, improving analytical sensitivity. This enhanced precision translated into stronger predictive performance, with the dPCR-based approach achieving higher discriminatory power for therapy response compared to prior qPCR analyses.(4)

Similarly, in endometrial cancer research, digital PCR was used to verify somatic mutations in patient-derived organoids by precisely measuring variant allele frequency for genes such as PIK3CA, KRAS, and TP53. Absolute quantification using the QuantStudio Absolute Q System allowed direct comparison between primary tumors and matched organoids, supporting evaluation of targeted therapies such as alpelisib or gedatolisib relative to standard chemotherapy.(7)

Closing the translational gap in precision oncology research

For translational oncology researchers, the focus must shift from biomarker discovery alone to implementing workflows that can withstand subsequent verification. Standardized, end-to-end pipelines that combine automated extraction with high-precision detection methods provide the reproducibility, scalability, sensitivity, and speed required for this transition. By minimizing variability, these workflows strengthen confidence in complex molecular measurements across sample types and study sites.

Together, the examples presented here highlight a broader shift: complex molecular signatures can now be quantified with the precision and consistency necessary for multi-center validation. For translational laboratories, adopting standardized workflows is a practical step toward bridging the gap between molecular insights and implementation in precision oncology research.

For more information on how Applied Biosystems solutions can assist you in your oncology research, visit thermofisher.com/abcancerresearch.

For Research Use Only. Not for use in diagnostic procedures. © 2026 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.

References

1.         Naranbat D, Herdes E, Tapinos N, Tripathi A. Review of microRNA detection workflows from liquid biopsy for disease diagnostics. Expert Reviews in Molecular Medicine. 2025 Jan;27:e11.

2.         Takizawa S, Matsuzaki J, Ochiya T. Circulating microRNAs: Challenges with their use as liquid biopsy biomarkers. Cancer Biomark. 2022;35(1):1–9.

3.         Levati L, Bassi C, Mastroeni S, Lupini L, Cappellini GCA, Bonmassar L, et al. Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy. Cancers [Internet]. 2022 Jul 29 [cited 2026 Feb 18];14(15). Available from: https://www.mdpi.com/2072-6694/14/15/3706

4.         De Gregorio A, Sacconi A, Mandoj C, Valenti F, De Pascale V, Madonna G, et al. Development of an innovative duplex digital PCR assay for circulating MiRNA ratio quantification in metastatic melanoma. J Transl Med. 2025 Aug 13;23(1):904.

5.         Allegretti M, Joun DJ, Urbani G, De Pascale V, Ganci F, Pellini R, et al. miRquad: first-in-class dPCR multiplex TaqMan Advanced clinical research assay for microRNA detection in head and neck cancer. J Exp Clin Cancer Res. 2025 Dec 20;45(1):26.

6.         Moldovan L, Batte KE, Trgovcich J, Wisler J, Marsh CB, Piper M. Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med. 2014 Mar;18(3):371–90.

7.         Vaccarella S, Bruno V, Orlandi G, Covino DA, Frascolla C, Pulito C, et al. Dissecting endometrial cancer complexity in response to standard and targeted therapies. Cell Death Dis. 2025 Nov 28;16(1):873.